Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.40 |
| ▸ | NT5E | P21589 | 2/20 | 0.40 |
| ▸ | TYMP | P19971 | 4/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.32 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.32 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.32 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17223096 | 1.00 | POLB (0.57) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL17223098 | 1.00 | POLB (0.57) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL14049948 | 0.95 | POLB (0.58) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL12724655 | 0.89 | POLB (0.46) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL13897164 | 0.89 | POLB (0.46) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL6932396 | 0.89 | POLB (0.59) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL17992980 | 0.88 | POLB (0.59) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL12724971 | 0.87 | POLB (0.46) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL13897166 | 0.87 | POLB (0.46) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL23157266 | 0.86 | POLB (0.56) | POLBABL1RIN1P2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-04 | — | — | US | disclosed |
| EP-2921499-B1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACIDS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-01-22 | — | — | EP | disclosed |
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-09 | — | — | US | disclosed |
| US-20150315229-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-05 | — | — | US | disclosed |
| EP-2921499-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | Takeda Pharmaceutical Company Limited (JP) | 2015-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315229-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | POLM, POLRMT, RNMT | POLB 15/4885ABL1 2284/4885RIN1 2508/4885 |
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | RNGTT, POLR2H, POLR2E | POLB 31/4885ABL1 2954/4885RIN1 2972/4885 |
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | RNGTT, POLR2H, POLR2E | POLB 46/4885ABL1 2128/4885RIN1 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.